ESR1 and cancer: Notably, another study demonstrated that BC patients diagnosed with the more aggressive triple negative BC (TNBC) subtype had significantly lower serum VD levels than those with estrogen receptor positive (ER+) BC, with both cancer groups having lower VD levels than those with benign breast disease [34].